PUBLISHING IN PEER-REVIEWED JOURNALSUnbiased and science-based, IPC’s work deepens the understanding of psoriasis and its treatment, directly impacting how patients around the world are treated. Below is a list of publications developed by IPC Board Members and Councilors on behalf of IPC. We have included the abstract for each publication and a link to PubMed to find the full copy.
Arnon D. Cohen, Ronald Vender, Luigi Naldi, Robert E. Kalb, Tiago Torres, Murlidhar Rajagopalan, Joelle van der Walt, Lluís Puig, Helen S. Young. JAAD International. 2020 Sept 25. doi: 10.1016/j.jdin.2020.09.006.
Golbari NM, van der Walt JM, Blauvelt A, Ryan C, van de Kerkhof P, Kimball AB. J Eur Acad Dermatol Venereol. 2020 Sep 25. doi: 10.1111/jdv.16966.
Hoegsberg, Iversen, Lange, Bissonette, Carvalho, van de Kerkhof, Kirby, Kleyn, van der Walt JM7, Wu JJ8, Lynde. J Dermatolog Treat. 2020 Mar 6:1-6. doi: 10.1080/09546634.2020.1724250. [Epub ahead of print]
Background: Currently, no formalized international consensus guidelines exist to direct optimal topical
treatment including long-term treatment.
Objective: In this survey, we aim to examine if and which topicals are used in clinical practice in
long-term continuous treatment of psoriasis and how topicals are used in treating specific sites of
the body.
Methods: A questionnaire was distributed electronically to dermatologists from the International
Psoriasis Council (IPC) representing 26 countries.
Results: The top three topicals used across all severities of disease were topical corticosteroids, vitamin
D analogs, and potent topical corticosteroids in combination with vitamin D analogs. On locations
where the skin is thin, flexural and genital psoriasis, lower potency topical corticosteroids were
used, whereas on other sites, in particular in palmoplantar psoriasis, superpotent topical corticosteroids
and combination vitamin D analogs/corticosteroids were used.
Conclusions: It is relevant to optimize localized therapy for all severities of psoriasis reconciling disease
activity (stable vs. unstable disease), localization of the lesions and the individual patient and
his/her perspectives on disease control. Topical therapies are valuable treatments for classical mild disease
and may have a position in some patients with more severe manifestations. Link to article
Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, Blauvelt A. Journal of the American Academy of Dermatology (2019), doi: https://doi.org/10.1016/ j.jaad.2019.08.026.
BACKGROUND: Psoriasis severity categories have been important tools for clinicians to use in treatment decisions as well as to determine eligibility criteria for clinical studies. However, due to the heterogeneity of severity classifications and their lack of consideration for the impact of psoriasis involvement of special areas or past treatment history, patients may be mis-categorized, which can lead to under-treatment of psoriasis.
OBJECTIVE: To develop a consensus statement on the classification of psoriasis severity.
METHODS: A modified Delphi approach was developed by the International Psoriasis Council to define psoriasis severity.
RESULTS: After completion of the exercise, seven severity definitions were preferentially ranked. This most preferred statement rejects the mild, moderate and severe categories in favor of a dichotomous definition: Psoriasis patients should be classified as either candidates for topical therapy or candidates for systemic therapy; the latter are patients who meet at least one of the following criteria: 1) BSA > 10%, 2) Disease involving special areas, 3) Failure of topical therapy.
LIMITATIONS: This effort might have suffered from a lack of representation by all relevant stakeholders, including patients.
CONCLUSION: The consensus statement describes two categories of psoriasis severity, while accounting for special circumstances where patients may require systemic therapy. Link to PubMed>
congress coverage SID 2021 Read the psoriasis highlights from the SID 2021 congress learn more
Latest news PsoProtect Registry Data UpdateSeptember 13, 2021Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1,205 cases. July Update on PsoProtect Registry DataJuly 12, 2021Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1,147 cases. Expert Opinion: Coronavirus disease 2019 (COVID‐19)‐associated hospitalization and mortality in patients with psoriasis: A population‐based studyJuly 07, 2021IPC Councilor, Luigi Naldi, MD, shares his expert opinion on a population-based study of COVID-19 - associated hospitalization and mortality in patients with psoriasis. Grand Rounds tutorial on IPC's psoriasis severity reclassificationJune 21, 2021The AbbVie program features IPC Board Member Bruce Strober’s Grand Rounds, a tutorial explaining the current method of measuring the severity of psoriasis, why this limits proper care and treatment for psoriasis patients, how IPC’s Disease Severity Reclassification Project solves these problems, and how clinicians can implement this new classification method. More News